Vaxart (OTCMKTS:VXRT) Stock Breaks Below 200 Day Moving Average – What’s Next?

Vaxart, Inc. (OTCMKTS:VXRT) shares passed below its 200-day moving average during trading on Tuesday. The stock has a 200-day moving average of $0.57 and traded as low as $0.4530. Vaxart shares last traded at $0.49, with a volume of 89,499 shares.

Wall Street Analysts Forecast Growth

Separately, Zacks Research raised Vaxart to a “hold” rating in a research report on Thursday, July 9th. One investment analyst has rated the stock with a Hold rating. According to data from MarketBeat, the stock presently has an average rating of “Hold”.

Vaxart Stock Down 7.2%

The firm’s 50-day moving average price is $0.48 and its 200 day moving average price is $0.56. The firm has a market cap of $107.47 million, a P/E ratio of 2.76 and a beta of 1.05.

Vaxart (OTCMKTS:VXRT) last posted its quarterly earnings data on Thursday, August 6th. The biotechnology company reported ($0.06) EPS for the quarter, topping analysts’ consensus estimates of ($0.12) by $0.06. Vaxart had a return on equity of 53.04% and a net margin of 15.88%. The company had revenue of $27.18 million for the quarter, compared to the consensus estimate of $26.21 million. On average, equities analysts predict that Vaxart, Inc. will post -0.68 earnings per share for the current year.

Vaxart Company Profile

Vaxart, Inc is a clinical-stage biotechnology company focused on developing oral recombinant vaccines. Unlike conventional injectable vaccines, Vaxart’s vaccine candidates are designed to be administered as tablets, with the goal of stimulating both systemic and mucosal immune responses.

The company’s research programs have focused on infectious diseases including coronavirus infections, influenza and norovirus. Vaxart has developed vaccine candidates using its oral vaccine platform and has evaluated them in clinical studies, but the company does not have a marketed vaccine product.

Vaxart is based in the United States and conducts its research and clinical development activities primarily through U.S.-based operations and collaborations.